Thank you very much.
You're very correct. We created an expert review panel to identify and recommend the most viable options for securing supplies of isotopes over the medium to long term. They have been meeting since we announced them.
To answer the last part of your question, technical versus business plan, we're actually trying to encapsulate both. I will tell you the members of the expert panel to give you an indication of the flavour.
The chair of the panel is Peter Goodhand, who is a patient advocate for the Canadian Cancer Society. He is actually president of the Canadian Cancer Society. Dr. Éric Turcotte is on our panel. He is one of Canada's foremost nuclear medicine researchers. Richard Drouin is counsel in the law firm of McCarthy Tétrault to help us on the business side of it. Dr. Thom Mason, one of the world's leading nuclear scientists, is at the Oak Ridge National Lab in the United States, but he is Canadian, having been brought up in Dartmouth, Nova Scotia. He's adding the expertise to it.
On the MAPLEs question specifically, the call for proposals process has provided interested organizations the opportunity to raise their ideas regarding the MAPLEs for the experts' consideration. Not knowing what the panel specifically is considering, I would assume, because we have seen some press reports, that the panel will be taking a look at the MAPLEs. They possess the inherent capabilities to look at it from a business and a technological point of view.